{"created":"2023-06-20T15:47:24.790038+00:00","id":1949,"links":{},"metadata":{"_buckets":{"deposit":"ddc4216d-031c-42e7-9d01-46014640264b"},"_deposit":{"created_by":4,"id":"1949","owners":[4],"pid":{"revision_id":0,"type":"depid","value":"1949"},"status":"published"},"_oai":{"id":"oai:hama-med.repo.nii.ac.jp:00001949","sets":["1:11"]},"author_link":["4941","4942","4943","4944"],"item_3_biblio_info_5":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"1985-05-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"5","bibliographicPageEnd":"702","bibliographicPageStart":"696","bibliographicVolumeNumber":"37","bibliographic_titles":[{"bibliographic_title":"日本産科婦人科學會雜誌","bibliographic_titleLang":"ja"}]}]},"item_3_description_9":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"婦人科領域悪性腫瘍患者血清および組織中にて,腫瘍胎児性蛋白の一つと考えられる胎盤由来Leucine Aminopeptidase(P-LAP)を測定し,腫瘍マーカーとしての意義を検討した.(1)良性腫瘍患者血清中のP-LAP活性:非妊健常人,子宮筋腫および良性卵巣腫瘍血清中のP-LAP活性はそれぞれ,6.0±2.4,6.9±1.0および6.8±1.4mg/dl/hで,良性腫瘍患者と非妊健常人との間には有意差が認められなかった.(2)悪性腫瘍患者血清中のP-LAP活性:子宮頚癌Ⅰ期6,7±0.4,Ⅱ期9.0±1,5,Ⅲ期10.4±2.0,Ⅳ期11.4±1.9および再発例13.9±4.3mg/dl/hで,卵巣悪性腫瘍Ⅰ期7.7±0.6,Ⅱ期8.2±1.5,Ⅲ期9.9±1.6,Ⅳ期13・2±2・0および再発例18.6±3,2mg/dl/hであった.したがって,子宮頚癌および卵巣悪性腫瘍では,m期,IV期と再発例で非妊健常人とくらべて統計的に有意な高値を示した.(3)血清AFP,CEAおよびFerritinとの相関:血清AFPとは相関係数r=0.084,CEAとはr=0.102でP・LAPとは相関関係が認められなかったが,Ferritinとはr=0.613と相関関係が認められた.(4)P-LAP長期測定症例:悪性腫瘍患者8例の血清中P-LAP活性の連続測定を行ったところ,化学療法や放射線療法に反応し臨床症状が改善するときはP-LAP値の下降傾向,臨床症状が増悪さらには死亡の直前にはP-LAP値の上昇傾向が認められた.(5)卵巣悪性腫瘍6組織型の腫瘍組織中P-LAP活性を測定したところ,Krukenberg腫瘍(3例)を除く5組織型では,正常卵巣組織(4.9nmol/min/mgprotein)の約2倍の高値を示した.以上より,胎盤由来LAP(P-LAP)は婦人科領域悪性腫瘍の経過観察や予後判定に応用可能な臨床検査であることが示唆された","subitem_description_language":"ja","subitem_description_type":"Abstract"}]},"item_3_publisher_6":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"日本産科婦人科学会","subitem_publisher_language":"ja"}]},"item_3_relation_22":{"attribute_name":"NII論文ID","attribute_value_mlt":[{"subitem_relation_type":"isIdenticalTo","subitem_relation_type_id":{"subitem_relation_type_id_text":"110002218973","subitem_relation_type_select":"NAID"}}]},"item_3_rights_7":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"Copyright 日本産科婦人科学会","subitem_rights_language":"ja"},{"subitem_rights":"本文データは学協会の許諾に基づきCiNiiから複製したものである","subitem_rights_language":"ja"}]},"item_3_source_id_19":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"03009165","subitem_source_identifier_type":"ISSN"}]},"item_3_version_type_32":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"小林, 浩","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"4941","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"佐倉, 東武","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"4942","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"倉内, 修","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"4943","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"水谷, 栄彦","creatorNameLang":"ja"}],"nameIdentifiers":[{"nameIdentifier":"4944","nameIdentifierScheme":"WEKO"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2018-08-27"}],"displaytype":"detail","filename":"sankafujinka-37_5-696.pdf","filesize":[{"value":"628.1 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"sankafujinka-37_5-696.pdf","url":"https://hama-med.repo.nii.ac.jp/record/1949/files/sankafujinka-37_5-696.pdf"},"version_id":"7d7b1477-4f9c-459f-bba5-d7a676d7d0b5"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"Aminopeptidase","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Malignancy","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Oncodevelopmental proteins","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Tumor marker","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"婦人科悪性腫瘍における胎盤型Leucine Aminopeptidase(P-LAP)の測定意義","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"婦人科悪性腫瘍における胎盤型Leucine Aminopeptidase(P-LAP)の測定意義","subitem_title_language":"ja"}]},"item_type_id":"3","owner":"4","path":["11"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2013-08-27"},"publish_date":"2013-08-27","publish_status":"0","recid":"1949","relation_version_is_last":true,"title":["婦人科悪性腫瘍における胎盤型Leucine Aminopeptidase(P-LAP)の測定意義"],"weko_creator_id":"4","weko_shared_id":-1},"updated":"2023-08-02T07:20:31.706709+00:00"}